author-photo

Rashmi Malla

University of Texas MD Anderson Cancer Center

5

Papers

26

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)